<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981795</url>
  </required_header>
  <id_info>
    <org_study_id>MOR208C414</org_study_id>
    <nct_id>NCT04981795</nct_id>
  </id_info>
  <brief_title>realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy</brief_title>
  <acronym>realMIND</acronym>
  <official_title>realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy and Not Receiving Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REAL-MIND: Prospective multicenter observational study of patients with relapsed or&#xD;
      refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not&#xD;
      receiving autologous stem cell transplant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess treatment patterns, physician reported clinical&#xD;
      outcomes and patient-reported health-related quality of life (HRQoL) among patients diagnosed&#xD;
      with R/R-DLBCL not receiving autologous stem cell transplant (ASCT) and initiating second- or&#xD;
      third-line therapy. In addition, the aim of the Real-MIND study is to enroll patients&#xD;
      belonging to racial and ethnic minorities with a good gender, age and socio-economic status&#xD;
      balance in order to gain the best representation of the US population.&#xD;
&#xD;
      This non-interventional study will collect real-world data on treatments and clinical&#xD;
      outcomes as per usual care. This protocol does not recommend the use of any specific&#xD;
      treatments or assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Patterns</measure>
    <time_frame>2 Years</time_frame>
    <description>Number and percentage of treatment regimens used in R/R-DLBCL patients&#xD;
Number and percentage of different regimen sequences&#xD;
Treatment characteristics: Line of therapy, Treatment regimen, Treatment dosage,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician-reported clinical outcomes</measure>
    <time_frame>2 Years</time_frame>
    <description>Treatment effectiveness among R/R-DLBCL patients: Response assessment; criteria and imaging method used as reported by treating physician: DoR, ORR, CR, OS, EFS</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Adults (&gt; or = 18 years of age)</arm_group_label>
    <description>Adults (&gt; or = 18 years of age) diagnosed with relapsed or refractory DLBCL and initiating second- or third-line therapy meeting inclusion criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community Study- 75 sites across the USA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent by the patient or the patient's Legally Acceptable&#xD;
             Representative (LAR)&#xD;
&#xD;
          -  Age ≥18 years old at time of diagnosis of R/R-DLBCL&#xD;
&#xD;
          -  Histologically confirmed diagnosis of DLBCL according to World Health Organization&#xD;
             (WHO) classification, including histologically confirmed diagnosis of high-grade&#xD;
             lymphoma with double and triple hit: DLBCL with MYC and BCL2/BCL6 translocation&#xD;
             (double-hit) and MYC and BCL2 and BCL6 translocations (triple-hit)&#xD;
&#xD;
          -  Availability of data on first-line (and second-line, if applicable) DLBCL therapy&#xD;
             (with the minimum data required including treatment type, number of cycles and&#xD;
             response)&#xD;
&#xD;
          -  Relapsed or refractory DLBCL after at least one prior systemic therapy, and prior to&#xD;
             second- or third-line therapy for DLBCL (previous treatment can include ASCT)&#xD;
&#xD;
          -  Not planning to receive HD-ASCT at enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent participation in an interventional clinical study&#xD;
&#xD;
          -  Receiving ASCT therapy (note: having received ASCT in the past is not an exclusion&#xD;
             criterion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aizza Hassan, MPH</last_name>
    <phone>+1 857-289-1936</phone>
    <email>aizza.hassan@morphosys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Contorno</last_name>
      <phone>205-786-6987</phone>
      <email>daniel.contorno@alabamaoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc. - Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trevor Frosig</last_name>
      <phone>559-326-1222</phone>
      <email>tfrosig@ccare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Jardinico</last_name>
      <phone>224-534-7580</phone>
      <email>jjardinico@orchardhr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Parker</last_name>
      <phone>509-574-3493</phone>
      <email>bethparker@yvmh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.</citation>
    <PMID>32511983</PMID>
  </reference>
  <reference>
    <citation>Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.</citation>
    <PMID>34196165</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

